BMS-790052 is a first-in-class, highly-selective oral HCV NS5A inhibitor. NS5A is an essential component for hepatitis C virus (HCV) replication complex. BMS-790052 has broad genotype coverage and exhibits picomolar in vitro potency against genotypes 1a (EC50 50pm) and 1b (EC50 9pm). BMS-790052 produces a robust decline in HCV RNA (-3.6 logs after 48 hours from a single 100 mg) dosefollowing a single dose in patients chronically infected with HCV genotype 1.

June 21, 2017

prudect name : BMS-790052 is a first-in-class, highly-selective oral HCV NS5A inhibitor. NS5A is an essential component for hepatitis C virus (HCV) replication complex. BMS-790052 has broad genotype coverage and exhibits picomolar in vitro potency against genotypes 1a (EC50 50pm) and 1b (EC50 9pm). BMS-790052 produces a robust decline in HCV RNA (-3.6 logs after 48 hours from a single 100 mg) dosefollowing a single dose in patients chronically infected with HCV genotype 1.
BMS-790052

Synonyms: CAS NO: 1009119-64-5 (1214735-16-6) 1009119-65-6 HCLMolecular Formula: C₄₀H₅₀N₈O₆Molecular Weight: 738.88Purity: 98% minSolubility: In DMSOStorage: −20°C

CB839 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18503831